Treatment of Mycoplasma Pneumoniae Pneumonia in Severe Community-Acquired Pneumonia
This protocol applies to inpatient adults presenting with severe community-acquired pneumonia (CAP) who do not have risk factors for MRSA or Pseudomonas aeruginosa.
Severity is defined by the presence of one major criterion, or three or more minor IDSA/ATS criteria.The recommended strategy is combination antibiotic therapy — a β-lactam paired with either a macrolide or a respiratory fluoroquinolone. The complete regimen, including agent selection, duration guidance, and the full structured algorithm, is available in the protocol below.
The target endpoint is clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients reach stability within 48 to 72 hours; treatment continues until stability is achieved and for no less than 5 days total.
References
DOI: 10.1164/rccm.201908-1581ST
- In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):
- Validated definition includes either one major criterion or three or more minor criteria.
- In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1): a b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or a b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).
- Therefore, we recommend that combination therapy with a b-lactam plus a macrolide or a b-lactam plus a respiratory fluoroquinolone should be the treatment of choice for patients with severe CAP.
- As recent data supporting antibiotic administration for <5 days are scant, on a risk–benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days.
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days.
- Failure to achieve clinical stability within 5 days is associated with higher mortality and worse clinical outcomes.